Home › Companies › Gilead Sciences, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Gilead Sciences, Inc.’s Form 8-K, filed May 4, 2026 (Item 5.07 on EDGAR). Page generated October 13, 2026.
Meeting of April 30, 2026: 15 items on Gilead Sciences, Inc.’s Form 8-K, filed May 4, 2026: 3 approved · 3 not approved · 9 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided · This season’s results screens
Explore Gilead Sciences, Inc. in the interactive database Compare manager voting policies
These tallies are Gilead Sciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jacqueline K. Barton, Ph.D. | 1,013,176,696 | 21,056,724 | 938,657 | -- | 95,008,389 | 98% | Not verified | — |
| Elect Director: Jeffrey A. Bluestone, Ph.D. | 1,017,337,149 | 16,873,041 | 961,887 | -- | 95,008,389 | 98% | Not verified | — |
| Elect Director: Sandra J. Horning, M.D. | 1,002,426,858 | 31,078,619 | 1,666,600 | -- | 95,008,389 | 97% | Not verified | — |
| Elect Director: Kelly A. Kramer | 995,947,854 | 38,240,224 | 983,999 | -- | 95,008,389 | 96% | Not verified | — |
| Elect Director: Ted W. Love, M.D. | 1,016,607,688 | 17,592,385 | 972,004 | -- | 95,008,389 | 98% | Not verified | — |
| Elect Director: Harish Manwani | 995,710,468 | 38,469,820 | 991,789 | -- | 95,008,389 | 96% | Not verified | — |
| Elect Director: Daniel P. O'Day | 980,597,212 | 50,179,985 | 4,394,880 | -- | 95,008,389 | 95% | Not verified | — |
| Elect Director: Javier J. Rodriguez | 1,019,197,783 | 15,002,200 | 972,094 | -- | 95,008,389 | 99% | Not verified | — |
| Elect Director: Anthony Welters | 992,619,897 | 40,842,646 | 1,709,534 | -- | 95,008,389 | 96% | Not verified | — |
| The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received the following votes: | 1,046,350,569 | 82,831,295 | 998,602 | -- | -- | 93% | Approved | — |
| The Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes: | 954,325,805 | 77,503,947 | 3,342,325 | -- | 95,008,389 | 92% | Approved | — |
| The Company's stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. The proposal received the following votes: | 970,290,586 | 62,501,433 | 2,380,058 | -- | 95,008,389 | 94% | Approved | — |
| The Company's stockholders did not approve a stockholder proposal requesting an independent Board Chair policy. The proposal received the following votes: | 280,044,780 | 752,716,225 | 2,411,072 | -- | 95,008,389 | 27% | Not approved | — |
| The Company's stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access. The proposal received the following votes: | 134,042,210 | 886,986,584 | 14,143,283 | -- | 95,008,389 | 13% | Not approved | — |
| The Company's stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics. The proposal received the following votes: | 7,262,421 | 1,022,330,186 | 5,579,470 | -- | 95,008,389 | 0.8% | Not approved | — |
Source: Gilead Sciences, Inc., Form 8-K, filed with the SEC on May 4, 2026 — read the filing on EDGAR.
Each item below shows how the 1,366 asset managers that disclosed a Gilead Sciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 10 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jacqueline K. Barton, Ph.D.
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Jacqueline K. Barton, Ph.D.”): 1,013,176,696 for, 21,056,724 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 240 asset managers below reported 505,434,733 for, 269 against, 126,542 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,764,040 | 269 | 11 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,056,858 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,118,939 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.
Combines 13 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jeffrey A. Bluestone, Ph.D.
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Jeffrey A. Bluestone, Ph.D.”): 1,017,337,149 for, 16,873,041 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 240 asset managers below reported 505,434,788 for, 216 against, 126,542 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,764,095 | 216 | 11 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,056,858 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,118,939 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.
Combines 13 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Sandra J. Horning, M.D.
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Sandra J. Horning, M.D.”): 1,002,426,858 for, 31,078,619 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 240 asset managers below reported 505,390,665 for, 44,330 against, 126,553 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,763,923 | 379 | 22 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,056,858 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,118,939 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.
Combines 10 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Kelly A. Kramer
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Kelly A. Kramer”): 995,947,854 for, 38,240,224 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 240 asset managers below reported 505,344,242 for, 90,761 against, 126,543 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,763,840 | 470 | 12 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,056,858 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,118,939 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.
Combines 13 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Ted W. Love, M.D.
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Ted W. Love, M.D.”): 1,016,607,688 for, 17,592,385 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 240 asset managers below reported 505,434,805 for, 200 against, 126,542 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,764,112 | 200 | 11 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,056,858 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,118,939 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.
Combines 10 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Harish Manwani
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Harish Manwani”): 995,710,468 for, 38,469,820 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 240 asset managers below reported 504,893,610 for, 541,395 against, 126,543 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,763,811 | 501 | 12 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,056,858 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,118,939 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.
Combines 10 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Javier J. Rodriguez
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Javier J. Rodriguez”): 1,019,197,783 for, 15,002,200 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 240 asset managers below reported 505,444,814 for, 190 against, 126,542 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,764,121 | 190 | 11 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,056,858 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,118,939 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.
Combines 10 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Anthony Welters
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Anthony Welters”): 992,619,897 for, 40,842,646 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 240 asset managers below reported 505,369,620 for, 65,873 against, 126,553 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,763,764 | 536 | 22 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,056,858 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,118,939 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.
Combines 10 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Daniel P. O'Day
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Daniel P. O'Day”): 980,597,212 for, 50,179,985 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 239 asset managers below reported 505,308,613 for, 129,286 against, 126,590 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,763,633 | 629 | 59 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,600 | 107 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,056,858 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,118,939 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 239 asset managers. See all 239 in the interactive database.
Combines 8 wordings of this item as funds reported it.
94% Approved · of votes cast
Description as filed by funds: To approve the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan.
Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. The proposal received the following votes:”): 970,290,586 for, 62,501,433 against — passed, per its Form 8-K filed May 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Gilead Sciences, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (11 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “Adopt Incentive Stock Option Plan” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 249 asset managers below reported 501,188,776 for, 4,598,509 against, 126,949 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,763,639 | 652 | 32 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 386 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,499 | 208 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 0 | 3,393,694 | 0 | 0 | Against |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,056,858 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,118,939 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 249 asset managers. See all 249 in the interactive database.
Combines 30 wordings of this item as funds reported it.
92% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.
Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes:”): 954,325,805 for, 77,503,947 against — passed, per its Form 8-K filed May 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as presented in the Proxy Statement.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Gilead Sciences, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Say on Pay” (4 managers, 13,649 for, 120,181 against).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,763,274 | 1,005 | 45 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,499 | 208 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,759,326 | 1,006 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 0 | 4,442,896 | 0 | 0 | Against |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,056,858 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,118,939 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Fund voting reports, all 226 managers: 499,294,193 for, 5,335,772 against, 126,576 abstained, 946 not voted. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 64,806,769 | 0 | 0 | 0 | For |
| BlackRock | 58,910,265 | 5,676 | 0 | 0 | For |
| Capital Group | 42,193,272 | 0 | 386 | 0 | For |
| Invesco | 41,411,351 | 40 | 2 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 29,515,809 | 0 | 0 | 0 | For |
| T. Rowe Price | 28,823,285 | 12,003 | 0 | 0 | For |
| Capital Research Global Investors | 28,581,373 | 0 | 0 | 0 | For |
| Dodge & Cox | 24,231,666 | 0 | 0 | 0 | For |
| State Street | 23,311,737 | 429,050 | 0 | 0 | For |
| Vanguard | 13,028,213 | 0 | 0 | 0 | For |
| Wellington | 12,642,207 | 0 | 0 | 0 | For |
| Northern Trust | 11,478,345 | 100,015 | 0 | 0 | For |
| UBS | 8,446,814 | 0 | 0 | 0 | For |
| Charles Schwab | 8,337,674 | 0 | 0 | 0 | For |
| Nuveen | 7,605,658 | 260 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 6,831,583 | 0 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 130,711 | 6,140,978 | 0 | 0 | Against |
| Goldman Sachs | 6,218,575 | 0 | 0 | 0 | For |
| Amundi | 0 | 6,203,061 | 0 | 0 | Against |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0 | 6,048,355 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 5,303,173 | 0 | 0 | 0 | For |
| AllianceBernstein | 5,015,288 | 0 | 0 | 0 | For |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 4,645,927 | 0 | 0 | Against |
| WELLS FARGO CLEARING SERVICES, LLC | 4,587,651 | 0 | 0 | 0 | For |
| TD ASSET MANAGEMENT INC | 3,940,925 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1,174 managers: 596,492,489 for, 57,866,816 against, 1,194,351 abstained, 291,806 not voted, 16,415 unknown. Showing the 25 largest; see all in the interactive database.
Combines 5 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.
Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received the following vote”): 1,046,350,569 for, 82,831,295 against — passed, per its Form 8-K filed May 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Gilead Sciences, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (7 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 237 asset managers below reported 502,528,206 for, 2,368,674 against, 126,541 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,652,852 | 111,460 | 10 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,234,588 | 7,138 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,499 | 208 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,759,326 | 1,006 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,056,858 | 0 | 0 | 0 | For |
| Jackson National | 2,598,683 | 275,462 | 0 | 0 | Mixed |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,118,939 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 237 asset managers. See all 237 in the interactive database.
Combines 8 wordings of this item as funds reported it.
0.8% Not approved · of votes cast
Description as filed by funds: To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting.
Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics. The proposal received the following votes:”): 7,262,421 for, 1,022,330,186 against — failed, per its Form 8-K filed May 4, 2026 (Item 5.07).
Reported outcome: Not approved, in the filing’s own words: “The Company's stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics.”
Support: 0.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 252 asset managers below reported 596,912 for, 505,390,900 against, 919,280 abstained, 942 not voted, 4,108 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 73 | 114,764,176 | 74 | 0 | Against |
| Fidelity | 0 | 78,590,115 | 0 | 0 | Against |
| Capital Group | 0 | 67,499,643 | 0 | 0 | Against |
| BlackRock | 0 | 49,241,726 | 0 | 0 | Against |
| Invesco | 0 | 38,663,991 | 0 | 0 | Against |
| Dodge & Cox | 0 | 19,998,392 | 0 | 0 | Against |
| JPMorgan | 0 | 15,929,448 | 0 | 0 | Against |
| State Street | 0 | 14,747,707 | 0 | 0 | Against |
| T. Rowe Price | 0 | 13,108,314 | 0 | 0 | Against |
| Charles Schwab | 0 | 7,852,508 | 0 | 0 | Against |
| TIAA | 0 | 6,806,803 | 0 | 0 | Against |
| Hartford | 0 | 4,760,332 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 4,563,061 | 0 | 0 | Against |
| MFS | 0 | 4,442,896 | 0 | 0 | Against |
| American Century | 0 | 3,393,694 | 0 | 0 | Against |
| Pacer Funds Trust | 0 | 3,288,510 | 0 | 0 | Against |
| First Trust | 0 | 3,056,858 | 0 | 0 | Against |
| Jackson National | 0 | 2,874,145 | 0 | 0 | Against |
| Dimensional | 0 | 2,697,114 | 0 | 0 | Against |
| John Hancock | 0 | 2,429,733 | 0 | 0 | Against |
| WisdomTree | 0 | 2,118,939 | 0 | 0 | Against |
| INVESTMENT CO OF AMERICA | 0 | 1,947,854 | 0 | 0 | Against |
| ProShares | 0 | 1,945,965 | 0 | 0 | Against |
| Waddell & Reed | 0 | 1,945,339 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 0 | 1,914,333 | 0 | 0 | Against |
Showing the 25 largest of 252 asset managers. See all 252 in the interactive database.
Combines 5 wordings of this item as funds reported it.
13% Not approved · of votes cast
Description as filed by funds: To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting.
Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access. The proposal received the following votes:”): 134,042,210 for, 886,986,584 against — failed, per its Form 8-K filed May 4, 2026 (Item 5.07).
Reported outcome: Not approved, in the filing’s own words: “The Company's stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access.”
Support: 13% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 239 asset managers below reported 4,736,308 for, 499,828,231 against, 981,102 abstained, 942 not voted, 102 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 111,895 | 114,652,237 | 189 | 0 | Against |
| Fidelity | 0 | 78,590,115 | 0 | 0 | Against |
| Capital Group | 0 | 67,499,643 | 0 | 0 | Against |
| BlackRock | 29,619 | 49,212,107 | 0 | 0 | Against |
| Invesco | 0 | 38,663,991 | 0 | 0 | Against |
| Dodge & Cox | 0 | 19,998,392 | 0 | 0 | Against |
| JPMorgan | 0 | 15,929,448 | 0 | 0 | Against |
| State Street | 4,065 | 14,743,642 | 0 | 0 | Against |
| T. Rowe Price | 0 | 13,108,314 | 0 | 0 | Against |
| Charles Schwab | 0 | 7,852,508 | 0 | 0 | Against |
| TIAA | 0 | 6,806,803 | 0 | 0 | Against |
| Hartford | 1,006 | 4,759,326 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 4,563,061 | 0 | 0 | Against |
| MFS | 0 | 4,442,896 | 0 | 0 | Against |
| American Century | 0 | 3,393,694 | 0 | 0 | Against |
| Pacer Funds Trust | 0 | 3,288,510 | 0 | 0 | Against |
| First Trust | 0 | 3,056,858 | 0 | 0 | Against |
| Jackson National | 0 | 2,874,145 | 0 | 0 | Against |
| Dimensional | 0 | 2,697,114 | 0 | 0 | Against |
| John Hancock | 0 | 2,429,733 | 0 | 0 | Against |
| WisdomTree | 0 | 2,118,939 | 0 | 0 | Against |
| INVESTMENT CO OF AMERICA | 0 | 1,947,854 | 0 | 0 | Against |
| ProShares | 0 | 1,945,965 | 0 | 0 | Against |
| Waddell & Reed | 0 | 1,945,339 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 0 | 1,914,333 | 0 | 0 | Against |
Showing the 25 largest of 239 asset managers. See all 239 in the interactive database.
Combines 3 wordings of this item as funds reported it.
27% Not approved · of votes cast
Description as filed by funds: To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.
Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting an independent Board Chair policy. The proposal received the following votes:”): 280,044,780 for, 752,716,225 against — failed, per its Form 8-K filed May 4, 2026 (Item 5.07).
Reported outcome: Not approved, in the filing’s own words: “The Company's stockholders did not approve a stockholder proposal requesting an independent Board Chair policy.”
Support: 27% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Gilead Sciences, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Require Independent Board Chair” (11 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 232 asset managers below reported 85,054,544 for, 418,928,557 against, 126,559 abstained, 942 not voted, 102 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,057 | 114,650,238 | 28 | 0 | Against |
| Fidelity | 576,500 | 78,013,615 | 0 | 0 | Against |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 36,172 | 49,205,554 | 0 | 0 | Against |
| Invesco | 0 | 38,663,991 | 0 | 0 | Against |
| Dodge & Cox | 0 | 19,998,392 | 0 | 0 | Against |
| JPMorgan | 0 | 15,929,448 | 0 | 0 | Against |
| State Street | 4,065 | 14,743,642 | 0 | 0 | Against |
| T. Rowe Price | 0 | 13,108,314 | 0 | 0 | Against |
| Charles Schwab | 2,112 | 7,850,397 | 0 | 0 | Against |
| TIAA | 0 | 6,806,803 | 0 | 0 | Against |
| Hartford | 1,006 | 4,759,326 | 0 | 0 | Against |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 0 | 4,442,896 | 0 | 0 | Against |
| American Century | 0 | 3,393,694 | 0 | 0 | Against |
| Pacer Funds Trust | 0 | 3,288,510 | 0 | 0 | Against |
| First Trust | 0 | 3,056,858 | 0 | 0 | Against |
| Jackson National | 0 | 2,874,145 | 0 | 0 | Against |
| Dimensional | 0 | 2,697,114 | 0 | 0 | Against |
| John Hancock | 1,843,756 | 585,977 | 0 | 0 | Mixed |
| WisdomTree | 0 | 2,118,939 | 0 | 0 | Against |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 0 | 1,945,965 | 0 | 0 | Against |
| Waddell & Reed | 0 | 1,945,339 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 0 | 1,914,333 | 0 | 0 | Against |
Showing the 25 largest of 232 asset managers. See all 232 in the interactive database.
Not shown here: this season’s fund filings also report 2 items from the meeting of May 7, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 1,242,000,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.24% |
| 2 | Fidelity | 6.33% |
| 3 | Capital Group | 5.43% |
| 4 | BlackRock | 3.96% |
| 5 | Invesco | 3.11% |
| 6 | Dodge & Cox | 1.61% |
| 7 | JPMorgan | 1.28% |
| 8 | State Street | 1.19% |
| 9 | T. Rowe Price | 1.06% |
| 10 | Charles Schwab | 0.63% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 5.22% |
| 2 | BlackRock | 4.74% |
| 3 | Capital Group | 3.40% |
| 4 | Invesco | 3.33% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.38% |
| 6 | T. Rowe Price | 2.32% |
| 7 | Capital Research Global Investors | 2.30% |
| 8 | Dodge & Cox | 1.95% |
| 9 | State Street | 1.91% |
| 10 | Vanguard | 1.05% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| The Vanguard Group | 9.00% | DEF14A |
| BlackRock, Inc. | 8.19% | DEF14A |
| FMR LLC | 5.28% | 13G |
| State Street | 4.82% | 13F |
| JPMorgan Chase | 2.74% | 13F |
| Gilead Sciences, Inc. | 2.53% | 13D |
| Geode Capital | 2.39% | 13F |
| T. Rowe Price | 2.11% | 13F |
| Morgan Stanley | 1.89% | 13F |
| Invesco | 1.25% | 13F |
Percentages above are of 1,242,000,000 shares outstanding, as reported by Gilead Sciences, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Gilead Sciences, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 13, 2026; a live search always shows the current data.
At Gilead Sciences, Inc.'s shareholder meeting held April 30, 2026, in the 2025-2026 proxy season, 1,366 asset managers reported how they voted on 15 ballot items in their SEC Form N-PX filings, covering 23,717 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our Named Executive Officers as presented… — Gilead Sciences, Inc.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Gilead Sciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 4, 2026.
Gilead Sciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.